ARCHIVES

Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Letter to the Editors: Loss Of ET2 Would Be Disheartening, Member Of Study Section Says

February 20, 1998

In Brief: Sullivan Will Be Secretary Most Knowledgeable About Cancer Program; Ihde Names ‘JNCI’ Editor

January 6, 1989

FDA to refer false statements by regulated companies to SEC.

February 27, 2004

NCI Agrees To Offer New Screening RFP In The Future

May 28, 1976

Protocols Approved By NCI During January 2004

February 27, 2004

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

February 15, 2002